Robust predictive markers are needed in order to identify the relatively small subsets of patients whose tumours are likely to respond to EGFR-targeted therapies (Baselga, 2002; Castro, 2002; Arteaga and Baselga, 2003). Here, EGFR is linked to neoplasm.